Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Heterogeneous boosting advantage confirmed by real-world data: V-01 booster demonstrates high-quality protection
Published Time：
2022-04-13
An article published in The New England Journal of Medicine shows that real-world research results from Qatar indicate that a third dose of Pfizer vaccine as a booster after a two-dose primary immunization with Pfizer has a relative protection rate of 49.4% (95% CI: 47.1~51.6) against symptomatic Omicron infection; a third dose of Moderna vaccine as a booster after a two-dose primary immunization with Moderna has a relative protection rate of 47.3% (95% CI: 40.7~53.3) against symptomatic Omicron infection. Real-world research data from the UK shows that among subjects who received the adenovirus vaccine (AstraZeneca) as primary immunization, the absolute protection rate was 62.4% (95% CI: 61.8~63.0) two to four weeks after a booster dose of mRNA vaccine (Pfizer). An article published in Nature Medicine shows that real-world research data from the United States indicates that three doses of mRNA-1273 (Moderna) have an absolute protection rate of 62.5% (56.2%-67.9%) against Omicron infection.
Publicly available information shows that the sequential booster immunization phase III clinical trial of Lizhu monoclonal antibody was launched in Pakistan and Malaysia in October 2021. This clinical trial is the world's first phase III clinical trial with a strong and superior design focusing on the sequential booster protection rate based on two doses of inactivated vaccines. The results show that the absolute protection rate after sequential boosting with V-01 is 61.35%, with significant superiority, and no safety concerns were found. In addition, in the obtained effective gene typing samples, most samples were sequenced as Omicron (the rest are still undergoing second-generation sequencing). The clinical trial results show that V-01 sequential boosting can produce good protection against COVID-19 caused by Omicron infection.
It is worth mentioning that although Omicron is less toxic than Delta, the elderly are a high-risk group in the COVID-19 epidemic, and the Omicron variant still poses a high threat to the elderly. Increasing the vaccination coverage rate among the elderly will help reduce the risk of COVID-19 infection and the likelihood of death from COVID-19. In the phase III clinical trials conducted in Pakistan and Malaysia, data analysis of population subgroups showed that the protection rate of V-01 for people with underlying diseases was 71.83%, and the protection rate for high-risk groups (60 years old or older or with underlying diseases) was 61.19%. The results further indicate that V-01 has high protection for high-risk groups.
In addition, the results of a researcher-initiated clinical study showed that subjects who had received inactivated COVID-19 vaccines 5-7 months ago were given booster shots of inactivated COVID-19 vaccines, V-01, and Lizhu bivalent vaccine (Delta and Beta strains). Twenty-eight days after booster immunization, the neutralizing antibody levels against Omicron live virus for V-01 prototype vaccine and bivalent vaccine were 4.9 and 11.2 times that of the inactivated vaccine, respectively. Sequential boosting showed higher protective efficacy than homologous boosting. At the same time, sequential boosting with the bivalent vaccine can quickly increase the neutralizing antibody level of Omicron in subjects. Seven days after vaccination, the neutralizing antibody titer of Omicron pseudotype virus produced by subjects increased by 29.6 times compared to before vaccination, and increased to 95.8 times by day 14.
The results of this study generally indicate that sequential boosting with V-01 or bivalent vaccine after inactivated COVID-19 vaccines can significantly enhance the neutralizing antibody diversity of recipients, reduce immune escape, and is a preferred booster immunization strategy to cope with the Omicron variant and future prevalent variants.
Currently, in addition to the Omicron variant, new and increasingly elusive variants are constantly emerging. Establishing a better platform to accelerate the development of effective vaccines against various variant viruses will establish an effective immune barrier for China's epidemic prevention and control. It is understood that the Lizhu vaccine R&D technology platform is based on excellent vaccine platform technology transferred from the Chinese Academy of Sciences, which can quickly develop vaccines against various variant viruses. Currently, this platform has successfully developed vaccines for several WHO-concerned variants, including Beta, Delta, and Omicron, and can be mass-produced as needed. This may also mean that the Lizhu vaccine R&D technology platform is expected to undertake the important task of developing safe and effective vaccines, increasing the possibility of developing vaccines against COVID-19 variant strains in the short term, and having a positive significance for addressing the current severe epidemic.
Source: Cailian Press
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.